Thomas Steyer’s Prime Medicine PRME Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.58M Hold
1,240,843
0.02% 70
2026
Q1
$4.32M Hold
1,240,843
0.02% 95
2025
Q4
$4.31M Sell
1,240,843
-3,509,157
-74% -$15.6M 0.02% 78
2025
Q3
$26.3M Buy
4,750,000
+4,000,000
+533% +$16.3M 0.11% 70
2025
Q2
$1.85M Hold
750,000
0.01% 86
2025
Q1
$1.49M Hold
750,000
0.01% 88
2024
Q4
$2.19M Hold
750,000
0.01% 95
2024
Q3
$2.9M Hold
750,000
0.01% 99
2024
Q2
$3.85M Hold
750,000
0.02% 95
2024
Q1
$5.25M Buy
+750,000
New +$5.69M 0.02% 101

Other funds holding PRME

Thomas Steyer's PRME Position: Q2 2026 in Review

Thomas Steyer held its Prime Medicine (PRME) position steady in Q2 2026 at 1,240,843 shares worth $4.58M. The position accounts for 0.02% of the portfolio, ranked #70.

Thomas Steyer first reported a position in PRME in Q1 2024 and has held it in 10 quarters since. The position peaked at $26.3M in Q3 2025. 186 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Thomas Steyer held 1,240,843 shares of Prime Medicine worth $4.58M as of Q2 2026.
  • Thomas Steyer left its Prime Medicine share count unchanged in Q2 2026.
  • Prime Medicine made up 0.02% of Thomas Steyer's portfolio in Q2 2026, its #70 holding.
  • Thomas Steyer first reported a position in Prime Medicine in Q1 2024 and has held it in 10 quarters since.
  • Thomas Steyer's Prime Medicine position peaked at $26.3M in Q3 2025.
  • 186 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.